IRIS
D'AMICO, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.887
AS - Asia 2.326
NA - Nord America 2.101
SA - Sud America 697
AF - Africa 46
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 4
Totale 8.073
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.032
IE - Irlanda 1.241
SG - Singapore 1.136
BR - Brasile 577
IT - Italia 408
HK - Hong Kong 402
RU - Federazione Russa 393
SE - Svezia 393
CN - Cina 318
VN - Vietnam 233
DE - Germania 129
FI - Finlandia 102
GB - Regno Unito 51
AR - Argentina 49
FR - Francia 43
IR - Iran 42
CA - Canada 30
IN - India 30
EC - Ecuador 29
BD - Bangladesh 28
ES - Italia 26
PL - Polonia 23
TR - Turchia 23
MX - Messico 22
ID - Indonesia 21
IQ - Iraq 19
NL - Olanda 19
AT - Austria 14
ZA - Sudafrica 14
PK - Pakistan 13
JP - Giappone 11
PY - Paraguay 11
AU - Australia 10
CO - Colombia 8
EG - Egitto 8
SA - Arabia Saudita 8
VE - Venezuela 8
BE - Belgio 7
MA - Marocco 7
CL - Cile 6
UA - Ucraina 6
AE - Emirati Arabi Uniti 5
CH - Svizzera 5
DO - Repubblica Dominicana 5
NP - Nepal 5
OM - Oman 5
RO - Romania 5
CR - Costa Rica 4
KZ - Kazakistan 4
PE - Perù 4
PH - Filippine 4
UY - Uruguay 4
A2 - ???statistics.table.value.countryCode.A2??? 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
JM - Giamaica 3
KE - Kenya 3
LT - Lituania 3
UZ - Uzbekistan 3
AL - Albania 2
AZ - Azerbaigian 2
GR - Grecia 2
MD - Moldavia 2
PS - Palestinian Territory 2
TH - Thailandia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BO - Bolivia 1
BW - Botswana 1
DK - Danimarca 1
GA - Gabon 1
HN - Honduras 1
IL - Israele 1
JO - Giordania 1
KG - Kirghizistan 1
KR - Corea 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NE - Niger 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
TG - Togo 1
TN - Tunisia 1
TO - Tonga 1
Totale 8.070
Salva come PNG Salva come JPEG
Città #
Dublin 1.239
Chandler 491
Hong Kong 396
Singapore 389
Nyköping 327
Ashburn 227
Santa Clara 169
Beijing 164
Princeton 134
Ho Chi Minh City 84
Wilmington 83
Helsinki 80
Munich 55
São Paulo 55
Hanoi 39
Dallas 33
Des Moines 32
Los Angeles 32
Rome 31
Milan 26
Shiraz 26
Turku 22
Ann Arbor 21
New York 21
Rio de Janeiro 21
Hillsboro 20
Moscow 20
Nuremberg 20
Seattle 20
Serra de' Conti 20
Warsaw 19
Frankfurt am Main 18
Bari 16
Curitiba 15
Naples 15
London 14
Assago 13
Thái Bình 13
Brooklyn 12
Foggia 12
Granada 12
Guangzhou 12
Brasília 11
Falkenstein 11
Belo Horizonte 10
Düsseldorf 10
Palermo 10
San Francisco 10
Tokyo 10
Cedar Knolls 9
Karachi 9
Quito 9
Campinas 8
Chicago 8
Denver 8
Kocaeli 8
Ninh Bình 8
Porto Alegre 8
Stockholm 8
Biên Hòa 7
Buenos Aires 7
Can Tho 7
Guayaquil 7
Jiaxing 7
Montreal 7
Shanghai 7
The Dalles 7
Vienna 7
Washington 7
Boston 6
Guarulhos 6
Johannesburg 6
Juiz de Fora 6
Lauterbourg 6
Mexico City 6
Pune 6
St Louis 6
Tehran 6
Ankara 5
Baghdad 5
Boardman 5
Borås 5
Bắc Ninh 5
Catania 5
Da Nang 5
Feira de Santana 5
Fortaleza 5
Frattamaggiore 5
Genoa 5
Hải Dương 5
Medole 5
Melbourne 5
Norwalk 5
Ribeirão Preto 5
Riyadh 5
Santos 5
Shenzhen 5
Sorocaba 5
Toronto 5
Villamagna 5
Totale 4.857
Salva come PNG Salva come JPEG
Nome #
La sindrome disesecutiva nel Mild Cognitive Impairment: aspetti clinici e possibilità riabilitative 193
Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 99
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 98
CCSVI and MS. A population-based case-control study in Catania, Sicily 93
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 91
Approccio clinico e possibilità di trattamento nella SLA 91
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 86
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 85
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 81
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal 79
An update on the pharmacological management of pain in patients with multiple sclerosis 78
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 78
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 77
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 76
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 76
Morfometria delle strutture del tronco encefalico in pazienti affetti da atassia spino-cerebellare tipo 2 (SCA 2): indicatore diagnostico e riabilitativo? 75
Comparison of Two Therapeutic Strategies in Active Relapsing-Remitting MS: Cyclophosphamide as Induction for 12 Months Follewed by Interferon Beta Versus Interferon Beta. A Two-Year Randomized Trial 74
Association between dietary intake and function in amyotrophic lateral sclerosis 73
Employment status in MS patients: a population-based study 73
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 73
Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy 73
Clinical Evolution of Relapsing Remitting Late Onset Multiple Sclerosis: A Nine Year Follow-Up Study 73
Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders 73
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 72
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 72
Review: Patient-reported outcomes in multiple sclerosis care 72
Psychological and social findings of patients with early multiple sclerosis or clinically isolated syndrome 71
Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives 71
Neuropsychological pattern of cognitive dysfunction in clinically isolated syndrome suggestive of MS 70
Dysphagia in Multiple Sclerosis 70
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 70
Can new chemical therapies improve the management of multiple sclerosis in children? 69
Effects of inpatient and outpatient rehabilitation setting on disability and quality of life of patients with multiple sclerosis: a randomized controlled study 69
Long term follow-up of combination therapy with inf-eta and cyclophosphamide relapsing-remitting MS patients 69
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 68
Use of a low-cost, commercially available gaming console (Nintendo-WII) foe rehabilitation of patients with multiple sclerosis: results of a pilot study 68
Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla 68
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 68
The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 67
The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS 66
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 66
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update 66
Negative prognostic impact of spinal demyelinating lesions at clinical onset in relapsing-remitting multiple sclerosis 65
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 65
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 65
The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study 64
Management of dysphagia in multiple sclerosis: current best practice 64
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 64
Cognitive dysfunction in multiple sclerosis. A population based study in Catania, Sicily 63
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 63
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis 63
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 62
Disability may influence patient willingness to partecipate in decision making on first-line therapy in multiple sclerosis 62
Unsatisfactory clinical and MRI response to DMTS in patients with late onset relapsing-remitting MS 62
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis 62
An update on the safety of treating relapsing-remitting multiple sclerosis 62
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 62
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 61
WII may improve physical abilities in multiple sclerosis: a randomized single blind study 60
The association of CCSVI and MS is not a risk factor for cognitive impariment in MS 60
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 60
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 59
Prevalence of pain in multiple sclerosis: a multicenter italian study 59
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 57
Metal/metalloid levels in cerebrospinal fluid in the bulbar-and spinal-onset amyotrophic lateral sclerosis 57
Treatment in worsening multiple sclerosis patients: new drugs are better than older ones? 57
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019 56
Multiple sclerosis patients preferences in decision making process 56
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 56
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 56
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 55
Multidisciplinary approach of amyotrophic lateral sclerosis: a centre experience 55
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 55
Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life 55
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 55
Gender related side effects of interferon-beta treatment in multiple sclerosis patients 55
Untreated relapsing remitting multiple sclerosis (RR-MS) patients. A single centre exprerience 54
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 54
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion 53
Palliative care in progressive multiple sclerosis 52
Five insights from the Global Burden of Disease Study 2019 51
Oral drugs in multiple sclerosis therapy: An overview and a critical appraisal 51
Conventional brain MRI could be a predictor of post partum relapse in multiple sclerosis 51
Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial 51
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 51
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk 50
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 50
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS 49
Myeloid-derived Suppressor Cells and Multiple Sclerosis 48
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 48
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 48
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 48
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study 48
Cognitive impairment in clinical isolated syndrome suggestive of multiple sclerosis: association with brain imaging and retinal nerve fiber layer thickness 47
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 47
Prevalence of patient-reported disphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire) 47
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 47
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 47
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer 46
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 46
Totale 6.496
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.086
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.086
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 0 0 0 0 24 0 1
2021/2022893 5 0 1 0 363 30 14 47 97 93 21 222
2022/20232.663 270 115 199 121 48 210 16 182 1.373 45 52 32
2023/2024480 57 47 31 32 75 58 30 52 26 19 19 34
2024/20252.309 110 72 68 42 41 265 341 107 586 150 230 297
2025/20262.404 213 529 582 887 186 7 0 0 0 0 0 0
Totale 8.774